LAUSR

PTEN gene deletion and protein loss occurs in 20-30% of prostate cancer (PCa) cases and leads to poor disease outcome. Loss of the PTEN tumor suppressor gene activates the PI3 kinase pathway and also appears to alter cellular interferon (IFN) responses. Recent evidence highlights the role of inflammation in the tumor microenvironment (TME) and its association with PCa disease progression. It is thus important to establish whether IFN response inflammatory biomarkers in PCa tumors are predictive of disease outcome in the context of PTEN status. The aim of this study is to determine if PTEN genomic and protein loss is associated with IFN response in the TME. We performed an in silico analysis of genomic and corresponding transcriptomic profiles PCa tumors (n=493) from the Genomic Data Commons (GDC) cohort to identify significant alterations in immune response pathways when PTEN was lost. Nexus Copy Number, v8.0 (BioDiscovery, Santa-Clara, CA, USA) was used for normalization, segmentation, and identification of corresponding copy number events of all genomic files in the GDC cohort. The GDC RNAseq dataset comprises the expression of 20,532 genes that were filtered using standard thresholds from Nexus Expression 3.0 (BioDiscovery, Santa-Clara, CA, USA). The filtering resulted in 6081 genes. Genes of interest were identified using the Gene Ontology (GO) Biological Function in Nexus Expression 3.0 with the keywords “Immune” and “Inflammatory” (http://geneontology.org/). Of the 449 selected immune genes, 124 (28%) were differentially expressed when the PTEN-loss group was compared to the PTEN-intact group. DAVID enrichment analysis showed upregulation of 16 pathways, in which three were directly associated with immune and inflammatory responses, including retinoic acid-inducible gene I (RIG-I-like) receptor signaling pathway (P Citation Format: Thiago Vidotto, Jeremy Andrew Squire, Madhuri Koti. PTEN loss associates with type I and II IFN response in prostate cancer [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; Sao Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr B30.